Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae- associated disease following vaccination with PCV-7: A multicountry analysis

Vaccine

Volumn 28, Issue SUPPL. 6, 2010, Pages

  Talbird, Sandra E ^a   Taylor, Thomas N ^b   Caporale, Joaquín ^c   Ismaila, Afisi S ^d,e   Gomez, Jorge ^f  

^a RTI HEALTH SOLUTIONS   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^d MCMASTER UNIVERSITY   (Canada)

^e GLAXOSMITHKLINE   (Canada)

^f GlaxoSmithKline   (Argentina)

Author keywords

Cost of illness; Nontypeable Haemophilus influenzae; Streptococcus pneumoniae

Indexed keywords

PNEUMOCOCCUS CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACUTE OTITIS MEDIA; ARTICLE; BACTEREMIA; CANADA; CHILD CARE; COST BENEFIT ANALYSIS; COST OF ILLNESS; GERMANY; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HUMAN; MEXICO; NONTYPEABLE HAEMOPHILUS INFLUENZAE; NORWAY; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

CHILD; CHILD, PRESCHOOL; GERMANY; HAEMOPHILUS INFECTIONS; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; NORTH AMERICA; NORWAY; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 78249275530     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.06.080     Document Type: Article

References (67)

1. Casey J.R., Pichichero M.E. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J 2004, 23(9):824-828.
2. Block S.L., Hedrick J., Harrison C.J., Tyler R., Smith A., Findlay R., et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J 2004, 23(9):829-833.
3. Murphy T.F. Vaccine development for non-typeable Haemophilus influenzae and Moraxella catarrhalis: progress and challenges. Expert Rev Vaccines 2005, 4(6):843-853. [Review].
4. O'Neill J.M., St Geme J.W., Cutter D., Adderson E.E., Anyanwu J., Jacobs R.F., et al. Invasive disease due to nontypeable Haemophilus influenzae among children in Arkansas. J Clin Microbiol 2003, 41(7):3064-3069.
5. European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Network [Internet]. London: Health Protection Agency. Invasive Haemophilus influenzae in Europe 2006 [updated 2006; cited 2009 November 20]. Available from: http://www.euibis.org/.
6. Morrow A., De Wals P., Petit G., Guay M., Erickson L.J. The burden of pneumococcal disease in the Canadian population before routine use of the seven-valent pneumococcal conjugate vaccine. Can J Infect Dis Med Microbiol 2007, 18(2):121-127.
7. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368(9546):1495-1502.
8. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9):810-815.
9. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(3):187-195.
10. Eskola J., Kilpi T., Palmu A., Jokinen J., Haapakoski J., Herva E., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001, 344(6):403-409.
11. Whitney C.G., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., Lynfield R., et al. Active Bacterial Core Surveillance of the Emerging Infections Program Network. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348(18):1737-1746.
12. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to nonpneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196(9):1346-1354.
13. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369(9568):1179-1186.
14. De Wals P., Robin E., Fortin E., Thibeault R., Ouakki M., Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008, 27(11):963-968.
15. Hausdorff W.P., Dagan R. Serotypes and pathogens in paediatric pneumonia. Vaccine 2008, 26(Suppl. 2):B19-23.
16. De Wals P., Carbon M., Sévin E., Deceuninck G., Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine in the province of Quebec, Canada. Pediatr Infect Dis J 2009, 28(9):e271-e275.
17. Kellner J.D., Vanderkooi O.G., MacDonald J., Church D.L., Tyrrell G.J., Scheifele D.W. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin Infect Dis 2009, 49(2):205-212.
18. Vestrheim D.F., Løvoll O., Aaberge I.S., Caugant D.A., Høiby E.A., Bakke H., et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008, 26(26):3277-3281.
19. Talbird S., Ismaila A., Taylor T. A steady-state, population-based model to estimate the direct and indirect effects of pneumococcal vaccines. Vaccine 2010, 28(Suppl. 6):G3-G13.
20. Nelson J.C., Jackson M., Yu O., Whitney C.G., Bounds L., Bittner R., et al. Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults. Vaccine 2008 September, 26(38):4947-4954.
21. McIntyre P.B., Berkey C.S., King S.M., Schaad U.B., Kilpi T., Kanra G.Y., et al. Dexamethasone as adjunctive therapy in bacterial meningitis: a meta-analysis of randomized clinical trials since 1988. JAMA 1997 September, 278(11):925-931.
22. Pomeroy S.L., Holmes S.J., Dodge P.R., Feigin R.D. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 1990 December, 323(24):1651-1657.
23. von Kries R., Siedler A., Schmitt H.J., Reinert R.R. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis 2000, 31(2):482-487.
24. Ciapponi A., Bardach A., García Martí S., Glujovsky D., Calcagno J., Aruj P., et al. Epidemiology of community acquired pneumonia in children of Latin American and the Caribbean 2008, Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires.
25. Ciapponi A., Bardach A., García Martí S., Glujovsky D., Calcagno J., Aruj P., et al. Systematic review of incidence, etiology and impact of health resources in community-acquired pneumonia in Latin America and the Caribbean 2008, Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires.
26. Brunton S. Current face of acute otitis media: microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine. Clin Ther. 2006 Jan, 28(1):118-123.
27. Gabastou J.M., Agudelo C.I., Brandileone M.C., Castañeda E., de Lemos A.P., Di Fabio JL Characterisation of invasive isolates of S. pneumoniae H. influenzae, and N. meningitis in Latin America and the Caribbean: SIREVA II, 2000-2005. Rev Panam Salud Publica 2008, 24(1):1-15. Grupo de Laboratorio de SIREVA II, [article in Spanish].
28. Wisløff T., Abrahamsen T.G., Bergsaker M.A., Løvoll Ø., Møller P., Pedersen M.K., et al. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 2006, 24(29-30):5690-5699.
29. Claes C., Reinert R.R., Vauth C., Greiner W. Health technology assessment. Heptavalenter Pneumokokkenkonjgat-Impfstoff 2008.
30. Statistics Canada [Internet]. The Consumer Price Index, June 2009. Catalogue no: 62-001X. Table 7: The Consumer Price Index for Canada, health and personal care component [cited 2009 November]. Available from: http://www.statcan.gc.ca/pub/62-001-x/2009006/tablesectlist-listetableauxsect-eng.htm.
31. Statistisches Bundesamt [Internet]. Consumer price index for Germany 2005=100 [updated 2008 December 31; cited 2010 April]. Available from: http://www.destatis.de/jetspeed/portal/cms/Sites/destatis/Internet/EN/Content/Statistics/TimeSeries/EconomicIndicators/BasicData/Content100/vpi101a,templateId=renderPrint.psml.
32. Statistics Norway [Internet]. Table 1. The Norwegian consumer price index by month. 1998=100. Annual average value [updated 2009; cited 2009 November 20]. Available from: http://www.ssb.no/kpi/tab-01.html.
33. Organisation for Economic Co-operation and Development (OECD) [Internet]. OECD Stat, PPPs and exchange rates. Table 4: Exchange rates, 2008, PPPs for GDP, 2008 [cited 2009 November 12]. Available from: http://stats.oecd.org/Index.aspx%3Fdatasetcode=SNA_TABLE4.
34. Linstone H.A., Turoff M. The Delphi method: techniques and applications 2002, University of Southern California, Los Angeles.
35. Instituto Mexicano del Seguro Social (IMSS). Diario Oficial de la Federación. Tomo DCLIV No. 20. México, D.F.; 2008.
36. Desarrollo Integral de la Familia (DIF) Nacional [Internet]. [Releases: deliver hearing aids for poor people] [cited 2010 February 11]. Available from: http://dif.sip.gob.mx/prensa/comunicados/%3Fcontenido=106.
37. Government of the State of Guanajuato [Internet]. [Cited 2010 February 11]. Available from: http://www.guanajuato.gob.mx/desarrollo/publico/fichas/noticia_detalle.php%3Fcom_id=7487.
38. Poirier B., De Wals P., Petit G., Erickson L.J., Pépin J. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada. Vaccine 2009, 27(50):7105-7109.
39. Petit G., De Wals P., Law B., Tam T., Erickson L.J., Guay M., et al. Epidemiological and economic burden of pneumococcal diseases in Canadian children. Can J Infect Dis 2003, 14(4):215-220.
40. De Wals P., De Serres G., Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. JAMA 2001, 285(2):177-181.
41. Waitzman N.J., Scheffler R.M., Romano P.S. The cost of birth defects 1996, University Press of America, Lanham.
42. Germany DRG data [Internet]. G-DRG-System 2008 [updated 2008; cited 2009 November 23]. Average of all DRGs for 2008 for meningitis (B72B), bacteraemia (T60E, T60D), pneumonia (E64B, E64C, E77C, E77E), and AOM (D62D, D62Z). Available from: Basic DRG value for cost calculation=€2800. http://www.gdrg.de/cms/index.php/inek_site_de/G-DRG-System_2008.
43. Kassenärztliche Bundesvereinigung [Internet]. Einheitlicher Bewertungsmaßstab (EBM) [Updated 2008; cited 2009 November 23]. Available from: http://www.kbv.de/8156.html.
44. Lauer-Taxe [Internet]. Lauer-Taxe Online Pharmaceutical Database [Updated 2008; cited 2009 November 23]. Available from: http://taxe.lauer-fischer.de/Taxe/taxe.aspx.
45. Gesundheitsberichtserstattung des Bundes (GBE) [Internet]. [Diagostic data of hospitals] 2007 AOM ICD-10: H65-H75 (Ad Hoc Tabelle) [cited 2008 October 21]. Available from: http://www.gbe-bund.de/.
46. Lloyd A., Patel N., Scott D.A., Runge C., Claes C., Rose M. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects. Eur J Health Econ 2008, 9(1):7-15.
47. Claes C. Graf von der Schulenburg JM. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 2003, 21(8):587-600.
48. Norwegian Directorate of Health [Internet]. [Updated 2007; cited 2009 November 20]. Rate for DRG 61 and DRG 62. Available from: http://www.helsedirektoratet.no/portal/page%3F_pageid=134,112387%26_dad=portal%26_schema=PORTAL%26language=english.
49. Statistics Canada. Income of individuals, by sex, age group and income source, 2006 constant dollars, annual. CANSIM Table 202-0407. Purchased October 15, 2008. Data on file.
50. Statistisches Bundesamt [Internet]. Wiesbaden [updated 2008 October 24 2008; cited 2009 Nov 23]. Available from: http://www.destatis.de/.
51. Statistics Norway [Internet]. Table 08055: Average monthly earnings for employees, full-time equivalents, by working hours, age-group and sex; Table 05111: Population aged 15-74, by labour force status, age and sex. [Updated 2007; cited 2009 November 20]. Available from: http://www.ssb.no/english/subjects.
52. Encuesta Nacional de Ocupación y Empleo (ENOE) [Internet]. Instituto Nacional de Estadística y Geografía. Segundo Trimestre 2008: Interactive database consultation [cited 2010 February 12]. Available from: http://www.inegi.gob.mx/inegi/default.aspx%3Fs=est%26c=10658.
53. Hurrelmann K, Andresen S for TNS Infratest Sozialforschung. Kinder in Deutschland 2007. 1. World Vision Kinderstudie. Frankfurt: Fischer Taschenbuch Verlag; 2007.
54. Federal Health Monitoring in Germany [Internet]. Diagnosis data of hospitals 2008 [cited 2010 February 11]. Available from: http://www.gbe-bund.de/.
55. Norwegian Patient Registry. Data provided by request; 2005.
56. Melegaro A., Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004, 22(31-32):4203-4214.
57. Senstad A.C., Surén P., Brauteset L., Eriksson J.R., Høiby E.A., Wathne K.O. Community-acquired pneumonia (CAP) in children in Oslo, Norway. Acta Paediatrica 2009, 98(2):332-336.
58. Statistics Canada [Internet]. Population by sex and age group: CANSIM Table 051-0001 [updated 2007 July 1; cited 2008 October]. Available from: http://www40.statcan.ca/l01/cst01/demo10a.htm.
59. Statistisches Bundesamt [Internet]. [Updated 2007 December 31; cited 2008 October]. Available from: http://www.destatis.de/.
60. Consejo Nacional de Población (CONAPO) [National Population Council (CONAPO)] [Internet]. Proyecciones de la población de México 2005-2050 [Population projections for Mexico 2005-2050] [updated 2006; cited 2010 April 23]. Available from: http://www.conapo.gob.mx/index.php%3Foption=com_content%26view=article%26id=36%26Itemid=234.
61. Statistics Norway [Internet]. Population, by age. Life tables, by sex and age [updated 2005; cited 2009 August 20]. Available from: http://statbank.ssb.no/statistikkbanken/Default_FR.asp%3FPXSid=0%26nvl=true%26PLanguage=1%26tilside=selecttable/MenuSelS.asp%26SubjectCode=02.
62. Beutels P., Thiry N., Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 2007, 25(8):1355-1367.
63. De Wals P., Erickson L., Poirier B., Pépin J., Pichichero M.E. How to compare the efficacy of conjugate vaccines to prevent acute otitis media?. Vaccine 2009, 27(21):2877-2883.
64. Johns B., Adam T., Evans D.B. Enhancing the comparability of costing methods: cross-country variability in the prices of non-traded inputs to health programmes. Cost Eff Resour Alloc 2006, 4:8.
65. Ekman M. Two essays in health economics: consumption and production by age with emphasis on health care expenditures and economic evaluation of beta-blocker therapy in heart failure 2001, Stockholm School of Economics, Stockholm.
66. Reinert R.R., Haupts S., van der Linden M., Heeg C., Cil M.Y., Al-Lahham A., et al. Invasive pneumococcal disease in adults in North-Rhine Westphalia, Germany, 2001-2003. Clin Microbiol Infect 2005, 11(12):985-991.
67. Leskinen K., Jero J. Complications of acute otitis media in children in southern Finland. Int J Pediatr Otorhinolaryngol 2004, 68(3):317-324.